[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients (original) (raw)
References
Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207–223 ArticlePubMedCAS Google Scholar
Loblaw A, Mendelson D, Talcott J, Virgo K, Somerfield M, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927–2941 ArticlePubMed Google Scholar
Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15–24 PubMedCAS Google Scholar
Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A sub analysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990;66:1009–1016 PubMedCAS Google Scholar
Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996;48:594–599 ArticlePubMedCAS Google Scholar
Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115–138 ArticlePubMedCAS Google Scholar
Nudell DM, Wefer AE, Hricak H, Caroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am 2000;38:213–229 ArticlePubMedCAS Google Scholar
May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66–69 ArticlePubMedCAS Google Scholar
Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patients with a rising prostate-specific antigen level. Semin Oncol 2003;30:616–634 ArticlePubMed Google Scholar
Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Group. J Urol 1998;159:2041–2046 ArticlePubMedCAS Google Scholar
Cher M, Bianco F Jr, Lam J, Davis L, Grignon D, Sakr W, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–1391 ArticlePubMedCAS Google Scholar
Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–1642 ArticlePubMedCAS Google Scholar
Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576–581 ArticlePubMedCAS Google Scholar
Dotan Z, Bianco F, Rabbani F, Easthman J, Fearn P, Scher H, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962–1968 ArticlePubMed Google Scholar
Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrum A. Positron emission tomography in urological oncology. J Urol 1998;159:347–356 ArticlePubMedCAS Google Scholar
Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31–35 ArticlePubMedCAS Google Scholar
Liu IJ, Zafar MB, Lai YH, Segall GM, Terri MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108–111 ArticlePubMedCAS Google Scholar
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–995 PubMedCAS Google Scholar
Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinshmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27;1415–1419 ArticlePubMedCAS Google Scholar
De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18–23 ArticlePubMed Google Scholar
Coleman R, De Grado T, Wang S, Baldwin S, Orr M, Reiman R, et al. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147 ArticlePubMed Google Scholar
Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549–555 PubMedCAS Google Scholar
De Grado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110–117 Google Scholar
Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274–292 ArticlePubMed Google Scholar
Seltzer M, Jahan S, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for 11C-acetate whole-body PET. J Nucl Med 2004;45:1233–1236 PubMedCAS Google Scholar
De Grado T, Reiman R, Price D, Wang S, Coleman R. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92–96 Google Scholar
Schmid D, John H, Zweifel R, Cservenyak T, Westera G, Goerres G, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623–628 PubMed Google Scholar
Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337–1340 ArticlePubMedCAS Google Scholar
De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331–335 PubMed Google Scholar
De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32–39 ArticlePubMed Google Scholar
Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317–324 ArticlePubMedCAS Google Scholar
Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742–748 ArticlePubMedCAS Google Scholar
Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642–1649 PubMedCAS Google Scholar
Hara T, Yuasa M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2oxyethylammonium [abstract]. J Nucl Med 1997;38(suppl):44P Google Scholar
Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187–199 PubMedCAS Google Scholar
De Grado T, Baldwin R, Wang S, Orr M, Liao R, Friedman H, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805–1814 Google Scholar
Price D, Coleman R, Liao R, Robertson C, Polascik T, De Grado T. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273–280 ArticlePubMed Google Scholar
Kwee S, Wei H, Sesterhenn I, Yun D, Coel M. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262–269 PubMed Google Scholar
Freedland S, Sutter M, Dorey F, Aronson W. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy: prostate-specific antigen. Urology 2003;61:365–369 ArticlePubMed Google Scholar